SRT 1720

• Description :

  SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H320

• Target :

  Autophagy; Sirtuin

• Type :

  Reference compound

• Related Pathways :

  Autophagy; Cell Cycle/DNA Damage; Epigenetics

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/srt-1720.html

• Purity :

  99.90

• Solubility :

  DMSO : 23.33 mg/mL (ultrasonic; adjust pH to 3 with H2O) |H2O : 12.99 mg/mL (ultrasonic; warming; adjust pH to 5 with 1 M HCl; heat to 60°C)

• Smiles :

  O=C(NC1=C(C=CC=C1)C2=CN3C(SC=C3CN4CCNCC4)=N2)C5=NC6=C(N=C5)C=CC=C6

• Molecular Formula :

  C25H23N7OS

• Molecular Weight :

  469.56

• Precautions :

  H315, H319, H320

• References & Citations :

  [1]Milne JC et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450 (7170) :712-6|[2]Baur JA, et al. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov. 2012 Jun 1;11 (6) :443-61|[3]Yao H, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest. 2012 Jun 1;122 (6) :2032-45.|[4]Yu L, et al. Protective effects of SRT1720 via the HNF1α/FXR signalling pathway and anti-inflammatory mechanisms in mice with estrogen-induced cholestatic liver injury. Toxicol Lett. 2016 Dec 15;264:1-11.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  SIRT1; SIRT2

• Citation 01 :

  Adv Sci (Weinh) . 2025 Apr;12 (15) :e2412109.|Aging Cell. 2021 Oct 3; e13491.|Am J Chin Med. 2020;48 (7) :1693-1713.|Authorea. September 07, 2022.|Biochem Biophys Res Commun. 2023 Jan 29:642:11-20.|Biochimie. 2020 Mar;170:10-20.|Biol Trace Elem Res. 2025 Sep 18.|Biol Trace Elem Res. 2025 Sep;203 (9) :4789-4806.|Biomed Pharmacother. 2023 Aug:164:114925.|Biomed Pharmacother. 2023 Aug:164:114987.|Biomedicines. 2023 Jun 1;11 (6) :1615.|Brain Res Bull. 2024 Nov:218:111101.|Cell Biol Int. 2025 Mar;49 (3) :262-276.|Cell Death Dis. 2024 Jun 28;15 (6) :462.|Cell Signal. 2024 Dec:124:111478.|Ecotoxicol Environ Saf. 2025 Sep 1:302:118629.|Elife. 2025 Apr 29:13:RP100406.|Environ Pollut. 2021 Jun 1:278:116840.|Environ Toxicol Pharmacol. 2024 Mar:106:104393.|Exp Eye Res. 2023 Jun:231:109464.|FASEB J. 2024 Jun;38 (11) :e23681.|Heliyon. 2024 May 22;10 (11) :e31654.|J Adv Res. 2025 Mar 31:S2090-1232 (25) 00218-8.|J Clin Transl Hepatol. Journal of Clinical and Translational Hepatology.|J Hazard Mater. 2025 Sep 15.|J Neuroinflammation. 2021 Dec 10;18 (1) :287.|J Orthop Surg Res. 2025 Aug 22;20 (1) :786.|J Transl Med. 2023 Jul 20;21 (1) :486.|J Transl Med. 2024 Feb 15;22 (1) :155.|Mol Biol Rep. 2020 Mar;47 (3) :2149-2159.|Mol Biol Rep. 2025 Mar 15;52 (1) :314.|Mol Med Rep. 2021 Jan;23 (1) :20.|Mol Med Rep. 2019 Feb;19 (2) :1040-1048. |Nat Commun. 2024 Aug 14;15 (1) :7000.|Oxid Med Cell Longev. 2021 Feb 27:2021:6659240.|Phytomedicine. 2022 Sep:104:154289.|Res Sq. 2024 May 31.|Sci Total Environ. 2024 Jan 1:906:167636.|Tissue Cell. 2025 Apr 2:95:102903.|Toxicol Lett. 2016 Dec 15:264:1-11.|Toxicol Res (Camb) . 2022 Jul 22;11 (4) :673-682.|Toxicol Sci. 2019 Aug 1;170 (2) :476-488.|Toxicology. 2024 Jun 10:153861.|Acta Pharm Sin B. 2023 Feb;13 (2) :559-576.|Biol Pharm Bull. 2025;48 (11) :1741-1752.|BMC Neurosci. 2025 Aug 30;26 (1) :56.|Cell Mol Immunol. 2022 Aug;19 (8) :872-882.|Food Funct. 2021 Jul 5;12 (13) :5821-5836.|Hypertension. 2016 Nov;68 (5) :1191-1199. |Int J Mol Med. 2019 Feb;43 (2) :839-849.|J Cachexia Sarcopenia Muscle. 2025 Feb;16 (1) :e13693.|Proc Natl Acad Sci U S A. 2019 Feb 19;116 (8) :2961-2966. |Research Square Preprint. 2024 Mar 19.|Research Square Print. 2022 Jul.|Sci Adv. 2022 Apr 8;8 (14) :eabj7110.

• CAS Number :

  [925434-55-5]